Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma

The predictors of response and survival in patients with hepatocellular carcinoma (HCC) receiving regorafenib remain unclear. This study aimed to delineate the determinants of response and survival after regorafenib and evaluate post-progression treatment and outcomes. We retrospectively enrolled 10...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: I-Cheng Lee, Yee Chao, Pei-Chang Lee, San-Chi Chen, Chen-Ta Chi, Chi-Jung Wu, Kuo-Cheng Wu, Ming-Chih Hou, Yi-Hsiang Huang
Format: Artigo
Langue:Inglês
Publié: MDPI AG 2022-04-01
Collection:Cancers
Sujets:
hepatocellular carcinoma
sorafenib
regorafenib
progression-free survival
overall survival
post-progression survival
Accès en ligne:https://www.mdpi.com/2072-6694/14/8/2014
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires